This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer (CEPAFIRI)

This study has been completed.
Aventis Pharmaceuticals
Information provided by:
Institut Bergonié Identifier:
First received: September 13, 2005
Last updated: December 29, 2011
Last verified: October 2007

The number of patients over 70 years old with cancer is increasing in France. This population is heterogenous: physiological functions, presence of co-morbidities, and autonomy can vary a lot between subjects of the same age. Physicians hesitate to treat them with optimal doses because they are afraid of the risk of toxicity in spite of the benefits of treatment. Fifty eight percent of gastric cancers are diagnosed in patients over the age of 70 in France. FOLFIRI (irinotecan, leucovorin and fluorouracil) chemotherapy appears to be a promising treatment for digestive cancer. It increases the level of response and survival without major toxicity. It becomes necessary to evaluate patients, to propose adapted treatments for their conditions.

The principal objectives are to demonstrate the efficacy of treatment, safety, survival and to find out if geriatric assessment data can help to better predict chemotherapy toxicity. The researchers plan to accrue 43 patients diagnosed with locally advanced or metastatic gastric cancer. They will receive FOLFIRI and 4 geriatric evaluations: before treatment, day 1 cycle 2, day 1 cycle 4 and at the end of chemotherapy. These evaluations include tests of cognitive functions (MMS), nutritional status (MNA), co-morbidity (CIRS-G), mobility (Get up and Go), activities (ADL; IADL), quality of life (QLQ-C30), depression (GDS-15) and Lachs-Balducci screening.

Condition Intervention Phase
Gastric Cancer Drug: Irinotecan associated to fluorouracil and leucovorin Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicentric Phase II Trial: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years Old and More Presenting Gastric Cancer Locally Advanced or Metastatic

Resource links provided by NLM:

Further study details as provided by Institut Bergonié:

Primary Outcome Measures:
  • Partial response after 2 months of treatment

Secondary Outcome Measures:
  • Toxicity
  • Geriatric evaluation
  • Survival

Estimated Enrollment: 43
Study Start Date: July 2004
Estimated Study Completion Date: July 2009

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 70 years of age or older
  • Gastric cancer, locally advanced or metastatic
  • No previous adjuvant treatment (surgery, radiotherapy, chemotherapy) in the last 6 months
  • One measurable lesion
  • ECOG < 3
  • Biology and biochemistry within normal limits
  • Life expectancy > 12 weeks

Exclusion Criteria:

  • Other palliative chemotherapy for this cancer
  • Other cancer in the last 5 years
  • Previous treatment with irinotecan
  • Atropine treatment not possible
  • Concomitant cancer therapy except bone radiotherapy
  • Metastases to brain or meninges with symptoms
  • Other severe pathology uncontrolled
  • Problem of compliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00210184

Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France, 33076
Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
Bordeaux, France, 33076
Hopital Robert Boulin
Libourne, France, 33700
Centre Hospitalier Universitaire de Pau
Pau, France, 64000
Clinique Francheville
Perigueux, France, 24000
Centre Hospitalier Universitaire de Villeneuve sur Lot
Villeneuve sur Lot, France, 47000
Sponsors and Collaborators
Institut Bergonié
Aventis Pharmaceuticals
Principal Investigator: Marianne FONCK, MD Institut Bergonié
  More Information Identifier: NCT00210184     History of Changes
Other Study ID Numbers: IB2004-18
Study First Received: September 13, 2005
Last Updated: December 29, 2011

Keywords provided by Institut Bergonié:
gastric cancer
geriatric evaluation

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017